Research Article

ALDH7A1 expression is associated with recurrence in patients with surgically resected non-small-cell lung carcinoma

Department of Radiation Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA

^‡Authors contributed equally

Department of Radiation Oncology, Thomas Jefferson University, G-301 Bodine Cancer Center, 111 South 11th Street, Philadelphia, PA 19107, USA

^‡Authors contributed equally

Search for more papers by this author

Rosana Eisenberg

Department of Pathology, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA

Search for more papers by this author

Heidi Chen

Department of Biostatistics, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA

Search for more papers by this author

Sandra J Olson

Department of Pathology, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA

Search for more papers by this author

Pierre P Massion

Division of Allergy, Pulmonology & Critical Care, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA

Search for more papers by this author

David P Carbone

Division of Hematology & Medical Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA

Search for more papers by this author

Bo Lu

* Author for correspondence

Department of Radiation Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA. .

Department of Radiation Oncology, Thomas Jefferson University, G-301 Bodine Cancer Center, 111 South 11th Street, Philadelphia, PA 19107, USA

Search for more papers by this author

Email the corresponding author at bo.lu@jefferson.edu

Published Online:7 May 2013https://doi.org/10.2217/fon.13.19

View article

Abstract

Aim: The purpose of this study was to describe the prognostic significance of ALDH7A1 in surgically treated non-small-cell lung carcinoma. (NSCLC). Materials & methods: We immunohistochemically analyzed ALDH7A1 expression in surgically resected NSCLC from 89 patients using a tissue microarray. Results: ALDH7A1 staining was positive in 43 patients and negative in 44 patients, with two tumor sections missing. For stage I NSCLC patients, ALDH7A1 positivity was associated with decreased recurrence-free and overall survival. Multivariate analysis demonstrated that ALDH7A1-expressing NSCLC tumors had a significantly higher incidence of lung cancer recurrence compared with patients with ALDH7A1-negative tumors, although there was no association with overall survival. Conclusion: For patients with NSCLC, low ALDH7A1 expression was associated with a decreased incidence of cancer recurrence. Specifically in stage I patients, negative staining for ALDH7A1 was associated with improved recurrence-free and overall survival, suggesting a predictive role in surgically treated patients.

Keywords:

References

1 Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin.60(5),277–300 (2010).
MedlineGoogle Scholar
2 Manser R, Wright G, Hart D, Byrnes G, Campbell DA. Surgery for early stage non-small cell lung cancer. Cochrane Database Syst. Rev.1,CD004699 (2005).
MedlineGoogle Scholar
3 Eramo A, Haas Tl, De Maria R. Lung cancer stem cells: tools and targets to fight lung cancer. Oncogene29(33),4625–4635 (2010).
Medline CASGoogle Scholar
4 Alison MR, Guppy NJ, Lim SM, Nicholson LJ. Finding cancer stem cells: are aldehyde dehydrogenases fit for purpose? J. Pathol.222(4),335–344 (2010).
MedlineGoogle Scholar
5 Jiang F, Qiu Q, Khanna A et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol. Cancer Res.7(3),330–338 (2009).
Medline CASGoogle Scholar
6 Deng S, Yang X, Lassus H et al. Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One5(4),e10277 (2010).
MedlineGoogle Scholar
7 van den Hoogen C, van der Horst G, Cheung H et al. High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res.70(12),5163–5173 (2010).
Medline CASGoogle Scholar
8 Prokopczyk B, Sinha I, Trushin N, Freeman WM, El-Bayoumy K. Gene expression profiles in HPV-immortalized human cervical cells treated with the nicotine-derived carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Chem. Biol. Interact.177(3),173–180 (2009).
Medline CASGoogle Scholar
9 Rose AE, Poliseno L, Wang J et al. Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression. Cancer Res.71(7),2561–2571 (2011).
Medline CASGoogle Scholar
10 Chan CL, Wong JW, Wong CP, Chan MK, Fong WP. Human antiquitin: structural and functional studies. Chem. Biol. Interact.191(1–3),165–170 (2010).
MedlineGoogle Scholar
11 Albert JM, Gonzalez A, Massion PP et al. Cytoplasmic clusterin expression is associated with longer survival in patients with resected non small cell lung cancer. Cancer Epidemiol. Biomarkers Prev.16(9),1845–1851 (2007).
Medline CASGoogle Scholar
12 Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature414(6859),105–111 (2001).
Medline CASGoogle Scholar
13 Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea – a paradigm shift. Cancer Res.66(4),1883–1890; discussion 1895–1886 (2006).
Medline CASGoogle Scholar
14 Baumann M, Krause M, Hill R. Exploring the role of cancer stem cells in radioresistance. Nat. Rev. Cancer8(7),545–554 (2008).
Medline CASGoogle Scholar
15 Ghotra VP, Puigvert JC, Danen EH. The cancer stem cell microenvironment and anti-cancer therapy. Int. J. Radiat. Biol.85(11),955–962 (2009).
Medline CASGoogle Scholar
16 Scopelliti A, Cammareri P, Catalano V, Saladino V, Todaro M, Stassi G. Therapeutic implications of cancer initiating cells. Expert Opin. Biol. Ther.9(8),1005–1016 (2009).
Medline CASGoogle Scholar
17 Eramo A, Lotti F, Sette G et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ.15(3),504–514 (2008).
Medline CASGoogle Scholar
18 Tirino V, Camerlingo R, Franco R et al. The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur. J. Cardiothorac. Surg.36(3),446–453 (2009).
MedlineGoogle Scholar
19 Bertolini G, Roz L, Perego P et al. Highly tumorigenic lung cancer CD133⁺ cells display stem-like features and are spared by cisplatin treatment. Proc. Natl Acad. Sci. USA106(38),16281–16286 (2009).
Medline CASGoogle Scholar
20 Woo T, Okudela K, Mitsui H et al. Prognostic value of CD133 expression in stage I lung adenocarcinomas. Int. J. Clin. Exp. Pathol.4(1),32–42 (2010).
MedlineGoogle Scholar
21 Patel M, Lu L, Zander DS, Sreerama L, Coco D, Moreb JS. ALDH1A1 and ALDH3A1 expression in lung cancers: correlation with histologic type and potential precursors. Lung Cancer59(3),340–349 (2008).
MedlineGoogle Scholar
22 Moreb JS, Baker HV, Chang LJ et al. ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells. Mol. Cancer7,87 (2008).
MedlineGoogle Scholar
23 Sullivan JP, Spinola M, Dodge M et al. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res.70(23),9937–9948 (2010).
Medline CASGoogle Scholar
24 Brocker C, Cantore M, Failli P, Vasiliou V. Aldehyde dehydrogenase 7A1 (ALDH7A1) attenuates reactive aldehyde and oxidative stress induced cytotoxicity. Chem. Biol. Interact.191(1–3),269–277 (2011).
Medline CASGoogle Scholar
25 Brocker C, Lassen N, Estey T et al. Aldehyde dehydrogenase 7A1 (ALDH7A1) is a novel enzyme involved in cellular defense against hyperosmotic stress. J. Biol. Chem.285(24),18452–18463 (2010).
Medline CASGoogle Scholar
26 van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Pelger RC, van der Pluijm G. The aldehyde dehydrogenase enzyme 7A1 is functionally involved in prostate cancer bone metastasis. Clin. Exp. Metastasis28(7),615–625 (2011).
MedlineGoogle Scholar
27 Comporti M. Lipid peroxidation and biogenic aldehydes: from the identification of 4-hydroxynonenal to further achievements in biopathology. Free Radic. Res.28(6),623–635 (1998).
Medline CASGoogle Scholar
28 Takahashi Y, Ogra Y, Suzuki KT. Synchronized generation of reactive oxygen species with the cell cycle. Life Sci.75(3),301–311 (2004).
Medline CASGoogle Scholar
29 Havens CG, Ho A, Yoshioka N, Dowdy SF. Regulation of late G1/S phase transition and APC Cdh1 by reactive oxygen species. Mol. Cell Biol.26(12),4701–4711 (2006).
Medline CASGoogle Scholar
30 Holyoake T, Jiang X, Eaves C, Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood94(6),2056–2064 (1999).
Medline CASGoogle Scholar
31 Cicalese A, Bonizzi G, Pasi CE et al. The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell138(6),1083–1095 (2009).
Medline CASGoogle Scholar
32 Richardson ME, Siemann DW. Tumor cell heterogeneity: impact on mechanisms of therapeutic drug resistance. Int. J. Radiat. Oncol. Biol. Phys.39(4),789–795 (1997).
Medline CASGoogle Scholar

Vol. 9, No. 5

Metrics

Downloaded 143 times

History

Published online 7 May 2013

Published in print May 2013

Information

Keywords

Financial & competing interests disclosure

This work was supported by NIH/National Center for Research Resources: Vanderbilt CTSA Grant UL1 RR024975. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

PDF download